This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Chronic myelogenous leukemia (CML)	IL-1 receptor accessory protein (IL-1RAP)	<p>A study in human CML samples suggests that antagonizing IL-1RAP could help treat CML, a disease caused by a genetic translocation in hematopoietic stem cells (HSCs). An analysis of samples from five subjects with CML showed that 99.9% of IL-1RAP-positive cells were CML stem cells, whereas 97.1% of IL-1RAP-negative cells were healthy HSCs. Treating primary CML stem cells with an antibody targeting IL-1RAP resulted in more cytotoxicity than did treating normal HSCs. Next steps include evaluating the safety and efficacy of IL-1RAP therapeutic antibodies in a CML mouse model.</p> <p>Cantargia AB has IL-1RAP-targeting mAbs in preclinical development for CML.</p> <p>SciBX 3(36); doi:10.1038/scibx.2010.1088 Published online Sept. 16, 2010</p>	<p>Use of IL-1RAP for diagnostic and therapeutic applications in leukemia covered by multiple issued and filed patents; available for licensing from Cantargia</p> <p>Contact: Eskil Söderlind, Cantargia AB, Lund, Sweden e-mail: eskil@cantargia.com</p>	<p>Järås, M. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Aug. 30, 2010; doi:10.1073/pnas.1004408107</p> <p>Contact: Thoas Fioretos, Lund University, Lund, Sweden e-mail: thoas.fioretos@med.lu.se</p>